Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label Extension of Studies M15-736 and M20-339 to Evaluate the Safety and Tolerability of 24-Hour Daily Exposure of ABBV-951 in Subjects With Advanced Parkinson's Disease

NCT04750226 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT04750226
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04750226 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label Extension of Studies M15-736 and M20-339 to Evaluate the Safety and Tolerability of 24-Hour Daily Exposure of ABBV-951 in Subjects With Advanced Parkinson's Disease
Lead sponsor
AbbVie
Phase
Phase 3
Overall status
Completed
Start date
February 18, 2021
Completion date
April 27, 2026
Enrollment
118 (actual)
Sites
52

Conditions

As the registry lists them; a condition with its own page is linked.

parkinson's disease (pd)